Company: AEMD
Filing Date: 2025-06-26
Form Type: 10-K
Source: 0001683168-25-004780
Chunk: 1047

Company: AETHLON MEDICAL INC
Filing Date: 2025-06-26
Form: 10-K
Item: Item 7
Chunk 1047
---
jections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of
changes in conditions or because the degree of compliance with the policies or procedures may deteriorate.

    (b)
    Changes in Internal Control Over Financial Reporting

There was no change in our
internal control over financial reporting during the last fiscal quarter ended March 31, 2025 that has materially affected, or is reasonably
likely to materially affect, our internal control over financial reporting.

ITEM 9B. OTHER INFORMATION

During the three
months ended March 31, 2025, none of our directors or officers entered into, modified or terminated a
“Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,” that were intended to satisfy the
affirmative defense conditions of Rule 10b5-1, in each case as defined in Item 408 of Regulation S-K.

ITEM 9C. DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT
INSPECTIONS

Not applicable.

 61 

PART III

ITEM 10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE

The names, ages and positions
of our directors and executive officers as of June 26, 2025 are listed below:

    NAMES
     
    TITLE OR POSITION(1)
     
    AGE
  
    James B. Frakes
     
    Chief Executive Officer, Chief Financial Officer and Director
     
    68

    Edward G. Broenniman
     
    Chairman and Director
     
    88

    Angela Rossetti
     
    Director
     
    71

    Chetan S. Shah, M.D.
     
    Director
     
    55

    Nicolas Gikakis
     
    Director
     
    58

    Steven P. LaRosa, M.D.
     
    Chief Medical Officer
     
    58

    (1)
    Our Board of Directors has determined that Mr. Broenniman, Mr. Gikakis, Ms. Rossetti and Dr. Shah meet the requirements to be determined as “independent directors” for all purposes, including Compensation Committee and Audit Committee purposes, under the Nasdaq Stock Market (“Nasdaq”) rules and for federal securities law purposes. Mr. Frakes is not independent, as he also functions as executive and officer